Crop Protection 2027: The New Global Map Reshaping the Industry
Acquisitions, biologicals, new chemistries, AI, formulations and strategic alliances are reshaping global crop protection as the industry enters 2027.
The global crop protection industry is entering the final quarter of 2026 in the middle of a transformation that has been building for years but is now revealing a much clearer competitive map for 2027. Multinationals are divesting assets, Asian companies are gaining scale, biological platforms are being acquired, new development alliances are emerging, and investment in artificial intelligence and differentiated formulations is accelerating. For U.S. growers, retailers and distributors, the significance goes well beyond corporate restructuring: competition is increasingly about combining innovation, manufacturing, registrations, agronomic evidence, distribution and technology - not simply owning the next molecule.
The movement is global and multidirectional. BASF has acquired a biological control company; Crystal Crop is moving to acquire FMC's commercial business in India; Tagros acquired global assets from Bayer; Rovensa Next has integrated a dozen businesses; Chinese companies are deepening investment in research and biotechnology; biological specialists are expanding internationally; and major multinationals continue to reshape their portfolios. At the same time, licensing agreements, partnerships and joint ventures are allowing companies to share risk and accelerate technologies into markets where building regulatory and commercial infrastructure from scratch could take years.
A Moving Map: Assets, Companies and Technologies Change Hands
One of the clearest developments is the redistribution of assets between established global players and companies seeking greater international scale. India offers a revealing example. In May, FMC agreed to sell FMC India Private Limited to Crystal Crop Protection for $252 million, a transaction expected to close by the end of 2026 subject to customary conditions. FMC said the deal includes its crop protection commercial business in India and supports a different go-to-market approach while allowing resources to be deployed toward higher-growth opportunities globally.
The transaction illustrates something larger than a corporate sale. While global companies concentrate capital and R&D around selected technologies and markets, regional players can use divestitures to acquire brands, registrations, distribution channels and market knowledge. That creates a more fluid global landscape in which companies historically associated with manufacturing or regional markets can develop into international commercial competitors. For the United States, that evolution matters because many of these players are increasingly connected to global active ingredient manufacturing, formulation and supply.
Another example is Tagros Chemicals' acquisition of Bayer's global flubendiamide business, completed around the transition from late 2025 into 2026. The transaction provided the India-based company with an established active ingredient, recognized brands and greater access to Latin America, Europe, the Middle East and Africa. Its broader strategy also includes value-added combination formulations and geographic expansion. This is not simply about buying an active ingredient; it is about acquiring a platform from which a company can build formulations, distribution and international market access.
Acquisitions are not limited to conventional chemistry. BASF completed its acquisition of AgBiTech on March 31, 2026, taking full ownership of a company specializing in biological insect control using naturally occurring viruses. AgBiTech has manufacturing operations in the United States, Australia and Brazil, giving the transaction direct relevance to the U.S. market as well as to one of the world's fastest-growing biological crop protection markets in Brazil. BASF said the acquisition is intended to accelerate the global scaling of those technologies and integrate them into its broader crop protection portfolio.
How the Global Crop Protection Map Is Changing
| Market movement | Examples | What it could mean for 2027 |
|---|---|---|
| Asset acquisitions | Crystal Crop-FMC; Tagros-Bayer | Brands, registrations and markets change hands |
| Biologicals | BASF-AgBiTech; Rovensa Next | Biologicals move into broader global platforms |
| Strategic alliances | Bayer-Kumiai; Helm-Parijat | Companies combine technology and market access |
| Licensing | FMC-Syngenta; Nutrichem-Albaugh/Rotam | Innovation can reach markets faster |
| Geographic expansion | India, China, Europe, Americas | Regional companies become global competitors |
| Industrial integration | Manufacturing + formulation + distribution | Greater control over cost and supply |
Partnerships and licensing agreements are another important part of the new map. Recent industry activity includes distribution agreements between Bayer and Kumiai Chemical in Japan; collaboration between Helm and Parijat Industries covering digital commerce, branded crop protection, technical manufacturing and international distribution; cooperation involving FMC and Syngenta around tetflupyrolimet for Asian rice markets; and intellectual-property licensing involving Nutrichem, Albaugh and Jiangsu Rotam around picoxystrobin. Intellectual property remains strategic, but it no longer needs to stay entirely inside one company to generate value.
The result is an industry with increasingly flexible corporate boundaries. One company may discover an active ingredient, another may formulate it, a third may register it and different partners may commercialize it depending on the region. That structure can spread development costs and shorten the path to market at a time when bringing a new crop protection solution through research and regulatory systems can require years. Future competitiveness may depend less on owning every part of the process internally and more on controlling an effective network of IP, formulation, registration, manufacturing, evidence and distribution.
Supply chains represent another critical part of this transformation. The pandemic, geopolitical tensions and disruptions across major trade routes demonstrated the risks associated with excessive dependence on individual suppliers or manufacturing regions. Dual sourcing, geographic diversification and backward integration have therefore become strategic considerations rather than purchasing decisions alone. For the U.S. crop protection market - which remains connected to a highly international active ingredient and intermediate supply chain - those changes can directly affect availability, cost and competitive positioning.
Geographic diversification works under the same logic. Companies heavily dependent on one crop, geography or growing season face greater exposure than businesses operating across multiple agricultural systems. Latin America is particularly important in this equation, led by Brazil and Argentina but extending across Mexico, Colombia, Peru, Chile, Paraguay and Uruguay. For U.S. companies, the region is both a major commercial market and an important testing ground for technologies facing different pest pressures, climates, cropping systems and application windows.
Biologicals, AI and Data: The Second Transformation Is Already Underway
If acquisitions are changing who controls assets, biologicals are changing what belongs inside a crop protection portfolio. Rovensa Next completed the integration of 12 legacy and acquired companies in January 2026, bringing capabilities and commercial relationships across Europe, Latin America and North America under a broader biological solutions platform. The underlying business model is significant: moving from individual products toward programs that combine agronomic knowledge, multiple technologies and grower economics.
New specialized companies are also attempting to scale from a different starting point. Veganic, launched in 2024, expanded into 15 countries and has used Latin America as a platform for growth, while targeting additional expansion in Brazil, other markets across the Americas, South Asia and Asia-Pacific. Its approach combines laboratory, greenhouse and field validation with partner training and expanded manufacturing capacity. The strategy illustrates a central challenge facing emerging biological companies: turning promising science into agronomic protocols that are simple, repeatable and economically viable enough to scale.
China adds another dimension. The development of companies such as Chengdu Newsun reflects increasing investment in biocontrol, biostimulants, microbial engineering, synthetic biology, natural-product discovery and AI-assisted research. Under this model, regulatory requirements, safety, mode of action, efficacy consistency, commercialization data and industrial scalability increasingly influence R&D decisions from an early stage. The competitive race therefore begins long before a product reaches a retailer or distributor.
Conventional chemistry, meanwhile, is not standing still. New active ingredients and modes of action remain critical as resistant weeds, insects and diseases continue to challenge production systems. The emerging crop protection landscape is therefore not a simple transition from chemistry to biology. Instead, it is becoming a broader technology race in which conventional active ingredients, biologicals, natural products, mixtures and advanced formulations increasingly coexist.
Formulation is also becoming a competitive battleground. Companies are investing in delivery systems, mixtures, co-formulants and proprietary formulation technologies designed to improve absorption, application characteristics or field performance. Examples across the industry include differentiated technologies from Adama and UPL. For companies without proprietary active ingredients, formulation science can provide a way to move away from purely price-driven generic competition and create products with measurable agronomic differentiation.
The New Layers of Crop Protection Competition
| Technology layer | Potential value | Commercial challenge |
|---|---|---|
| New chemistry | New modes of action | Resistance and regulation |
| Biocontrol | Additional pest-management tools | Consistency and scalability |
| Biostimulants | Stress and plant-performance management | Demonstrating agronomic response |
| Advanced formulations | Differentiation of known actives | Translating technology into value |
| AI-enabled R&D | Faster discovery and screening | Converting predictions into products |
| Digital agriculture | Diagnosis and recommendations | Connecting data to field decisions |
Yet the expansion of biologicals carries a challenge often hidden behind market-growth forecasts: a promising laboratory technology does not automatically become a commercially successful product. Raw materials, manufacturing processes, soil, weather, crop variety, application timing, tank mixes and agronomic management can all affect performance. Consistency therefore has to be built across the entire chain - from raw material and manufacturing to field application - while trials need to reproduce the conditions under which the product will actually be sold and used.
That makes local evidence increasingly valuable. A biological product may perform well in one season and respond differently in another. For biologicals and biostimulants, demonstrating that a product "works" is no longer enough. Companies need to establish what it was compared against, under which environments, across how many seasons, under what management practices and with what economic return. This is particularly relevant in the United States, where performance can vary substantially across production systems, soils and climates from the Midwest to the Great Plains, Southeast, Delta and specialty-crop regions.
The data behind agricultural technology reveal the same problem. In one analyzed case, a model designed to estimate cover-crop biomass using Sentinel-2 imagery initially achieved an R² of 0.72. But performance changed dramatically as validation became more demanding: R² fell to 0.47 when entire fields were held out, 0.07 when tested against a new geography and -0.13 when challenged with a season the model had never seen. R², or the coefficient of determination, indicates how much observed variation a model explains; a negative out-of-sample result can indicate performance worse than a simple baseline prediction.
The Same Model Can Tell Very Different Stories
| Validation scenario | Predictive performance (R²) | Interpretation |
|---|---|---|
| Random sampling units | 0.72 | Strong apparent performance |
| Entire fields | 0.47 | Predictive ability declines |
| New geography | 0.07 | Very limited predictive ability |
| Completely unseen season | -0.13 | Model fails to generalize |
The lesson extends well beyond digital agriculture. The same standard should increasingly apply to biologicals, biostimulants, new formulations and crop protection programs: What was the technology compared against? Where was it tested? How did it perform under unfavorable conditions? And what is the economic cost when it fails? In a market crowded with efficacy percentages, data claims and technological promises, the quality of validation itself may become as important a differentiator as the technology being validated.
Digitalization adds another layer. Platforms such as xarvio, FieldView, Cropwise and Granular illustrate how major agricultural companies have expanded beyond physical inputs into field mapping, diagnostics, recommendations and digital decision tools. Strategically, the opportunity is significant: moving from selling an individual product toward participating in the system that determines what should be applied, where, when and under which conditions. Crop protection is increasingly intersecting with sensors, satellite imagery, drones, predictive models and field-level data.
And one of the latest industry moves brings many of these trends together. In September, Corteva and Belgium-based Globachem announced an agreement to establish a 50/50 joint venture focused on developing, registering and commercializing differentiated crop protection solutions for Europe and the Americas. The structure is designed to combine technologies approaching commercialization with development, formulation and regulatory capabilities, illustrating how partnerships can be used to broaden pipelines without relying exclusively on internal discovery.
The biggest recent change, however, arrived on October 1, 2026. Corteva completed the spin-off of its advanced seed and genetics business and began its next chapter as a pure-play global crop protection company. The newly focused company has nearly 9,000 employees serving growers in approximately 110 countries. Between 2020 and 2025, its crop protection business increased revenue by more than $1 billion while expanding segment operating EBITDA margins by approximately 250 basis points.
The technology behind that restructuring is particularly relevant. Corteva reports an $11 billion crop protection pipeline and plans 12 new active ingredients over the next decade, including five biologicals. Differentiated technologies now account for approximately 65% of sales, while its R&D capabilities include microbial discovery, integrated development and predictive safety platforms. The move provides a current example of how biologicals, conventional chemistry, data and differentiated technologies are increasingly being assembled within a single crop protection strategy.
Viewed in isolation, Corteva's separation would be a major corporate restructuring. Viewed alongside BASF-AgBiTech, Crystal Crop-FMC, Tagros-Bayer, Rovensa Next's integration, emerging biological specialists, innovation from China and the broader expansion of licensing and development partnerships, it becomes part of a much larger transformation. Crop protection is simultaneously changing who controls assets, where products are manufactured, how technologies are discovered, what belongs in a portfolio and how solutions reach growers.
For the U.S. market, these developments matter well beyond company ownership. New global competitors can influence active ingredient sourcing, generic competition, biological portfolios, distribution agreements, product availability and the speed at which new technologies reach American farms. At the same time, the United States remains a critical R&D, regulatory and commercial market for many of the companies participating in this transformation, making it both a destination for innovation and a central part of the global competitive landscape.
The map emerging toward 2027 therefore does not point to the disappearance of chemistry or its automatic replacement by biologicals. Instead, the industry is becoming more integrated: new active ingredients alongside microorganisms and natural products; advanced formulations alongside digital tools; acquisitions complemented by licensing and partnerships; and agronomic decisions increasingly supported by field data and evidence.
The deeper change may be that competition in crop protection is expanding beyond the individual herbicide, fungicide or insecticide. Research, intellectual property, chemistry, biologicals, formulation, manufacturing, regulation, agronomic evidence, distribution and digital technology are becoming interconnected parts of the same competitive system. The global map is already moving - and the developments of 2026 show just how much broader the crop protection business could look as it enters 2027.
